GBX Summits works in conjunction with some of the world's most prominent leaders and visionaries across a variety of key industries in order to produce cutting edge programmes that simulate, educate and accelerate innovation.
Steering Committee And Speaker Faculty At A Glance
Steve Rees is currently Vice-President of Screening Sciences and Sample Management at AstraZeneca with global responsibility for High Throughput Screening, Compound Management, the human tissue BioBank and the provision of SAR biology support to preclinical discovery projects. Prior to joining AstraZeneca, Steve worked at GlaxoSmithKline for 24 years in various roles including that of Director of the Screening and Compound Profiling Department at GlaxoSmithKline in Stevenage. Steve has been responsible for developing hit identification, compound profiling and compound management strategies for AstraZenenca and previously GlaxoSmithKline. Steve has led multiple international collaborations and has sponsored the development and implementation of a range of cellular assay technologies for ion channel, GPCR and other target classes.
Steve has authored >60 scientific papers and has spoken at many international symposia including three occasions at the Society of Laboratory Automation and Screening (SLAS). He is currently Chair of the SLAS Europe Council . He is a member of the BBSRC panel of experts and is a member of the Board of Directors of ELRIG.
Dr Stevan Djuric is head of the global AbbVie Medicinal Chemistry Leadership Team at Abbott and is also responsible for the Discovery Chemistry and Technology organization within their Discovery organization and chemistry outsourcing activities. The group’s current efforts are focused on new initiatives in the areas of high throughput synthesis and purification, hit to lead chemistry, chemical biology including target identification proteomics and new enabling technology identification and development. He was named an AbbVie Distinguished Research Fellow in 2015. During his tenure at Abbott Laboratories, Dr Djuric has been a Project Leader for groups in the Immunoscience, Metabolic Disease, and Antiinfective areas. Several of these programs have advanced compounds into clinical development and to the market including Abbott’s proprietary rapamycin analog, Zotarolimus, currently licensed to Medtronics for use on their vascular stents, marketed in the United States and Europe. Dr Djuric has over 180 scientific publications, presentations and patents/applications pending. He has also given over 30 invited lectures at universities and national meetings. He is a member of several Editorial Advisory Boards including ACS Medicinal Chemistry Letters and, in addition, holds an Adjunct Professorship in the Department of Medicinal Chemistry at the University of Kansas.
Chas is Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. He is also a Visiting Professor in Neuroscience and Mental Health at Imperial College, London. Chas is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes.
Prior to coming back to Oxford, Chas was Vice President and Head of Biology at GlaxoSmithKline. He was involved in the identification of more than 40 clinical candidates for many gastro-intestinal, inflammatory and neuro-psychiatric diseases. More than 20 of these molecules progressed into patient studies and more than five of these delivered successful “Proof of Concept” data and hence progressed into late stage development. He was involved in the launch and development of the first treatment for Irritable Bowel Syndrome (Alosetron) and was the first to show that neurokinin NK1 antagonists are anti-emetic in preclinical and clinical studies.
Ted Torphy, PhD, has 30 years’ experience and a successful record in both small-molecule and large-molecule drug discovery. In addition, Dr. Torphy is a recognized leader in bringing open innovation to the pharmaceutical industry.
Steve Street joined Pfizer in 1985 and held a variety of roles within the Chemistry Department in Sandwich UK, before being appointed Head of Chemistry for Sandwich Discovery in 2001. Three years later, at the start of 2004, Steve moved to establish and lead the Chemistry Discipline across Worldwide Discovery.
Khusru Asadullah is Owner at Dermatological Practice and Consulting before this he was Vice President and Head of Global Biomarker at Bayer HealthCare Pharmaceuticals and headed inflammation and immunology research at Bayer Schering Pharma. He is a professor of medicine at the University hospital berlin. He graduated from the Medical School Charité in Berlin and Harvard Business School. Boston and is a board certified dermatologist and immunologist.